Journal of Inherited Metabolic Disease

, Volume 35, Issue 6, pp 949–954 | Cite as

Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β-galactosidases

  • Mahdi Amiri
  • Hassan Y. Naim
Rapid Communication


Miglustat is an oral medication that has approved indication for type I Gaucher disease and Niemann pick disease type C. Usually treatment with Miglustat is associated with occurrence of gastrointestinal side effects similar to carbohydrate maldigestion symptoms. Here, we studied the direct influence of Miglustat on the enzymatic function of the major disaccharidases of the intestinal epithelium. Our findings show that an immediate effect of Miglustat is its interference with carbohydrate digestion in the intestinal lumen via reversible inhibition of disaccharidases that cleave α-glycosidically linked carbohydrates. Higher non physiological concentrations of Miglustat can partly affect lactase activity. We further show that the inhibition of the disaccharidases function by Miglustat is mainly competitive and does not occur via alteration of the enzyme folding.


Gauche Disease Intestinal Lumen Brush Border Membrane Lactase Miglustat 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.









lactase-phlorizin hydrolase


brush border membrane



A Ph.D. scholarship provided by the German Academic Exchange Service (DAAD) to M.A. We thank Heshmat Akbari-Borhani for critical discussion.

Conflict of interest

This study has been supported by Actelion Pharmaceuticals GmbH.


  1. Alfalah M, Jacob R, Preuss U, Zimmer K-P, Naim H, Naim HY (1999) O-linked glycans mediate apical sorting of human intestinal sucrase-isomaltase through association with lipid rafts. Curr Biol 9:593–596PubMedCrossRefGoogle Scholar
  2. Andersson U, Butters TD, Dwek RA, Platt FM (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821–829PubMedCrossRefGoogle Scholar
  3. Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM (2011) Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 34:991–1001PubMedCrossRefGoogle Scholar
  4. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481–1485PubMedCrossRefGoogle Scholar
  5. Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts J, van Weely S, Zimran A (2007) Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 110:2296–2301PubMedCrossRefGoogle Scholar
  6. Hauri HP, Sterchi EE, Bienz D, Fransen JA, Marxer A (1985) Expression and intracellular transport of microvillus membrane hydrolases in human intestinal epithelial cells. J Cell Biol 101:838–851PubMedCrossRefGoogle Scholar
  7. Lindner R, Naim HY (2009) Domains in biological membranes. Exp Cell Res 315:2871–2878PubMedCrossRefGoogle Scholar
  8. Maiuri L, Raia V, Potter J, Swallow D, Ho MW, Fiocca R, Finzi G, Cornaggia M, Capella C, Quaroni A, Auricchio S (1991) Mosaic pattern of lactase expression by villous enterocytes in human adult-type hypolactasia. Gastroenterology 100:359–369PubMedGoogle Scholar
  9. Naim HY, Sterchi EE, Lentze MJ (1987a) Biosynthesis and maturation of lactase phlorizin hydrolase in the human small intestinal epithelial-cells. Biochem J 241:427–434PubMedGoogle Scholar
  10. Naim HY, Sterchi EE, Lentze MJ (1987b) Kinetics of the processing of newly synthesized sucrase-isomaltase (SI) in organ-cultures of human intestinal biopsies. Pediatr Res 22:111–111CrossRefGoogle Scholar
  11. Naim HY, Sterchi EE, Lentze MJ (1988) Structure, biosynthesis, and glycosylation of human small intestinal maltase-glucoamylase. J Biol Chem 263:19709–19717PubMedGoogle Scholar
  12. Quezada-Calvillo R, Sim L, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Sterchi EE, Robayo-Torres CC, Rose DR, Nichols BL (2008) Luminal starch substrate “brake” on maltase-glucoamylase activity is located within the glucoamylase subunit. J Nutr 138:685–692PubMedGoogle Scholar
  13. Robayo-Torres CC, Quezada-Calvillo R, Nichols BL (2006) Disaccharide digestion: clinical and molecular aspects. Clin Gastroenterol Hepatol 4:276–287PubMedCrossRefGoogle Scholar
  14. Rosenbaum AI, Maxfield FR (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem 116:789–795PubMedCrossRefGoogle Scholar
  15. Schmitz J, Preiser H, Maestracci D, Ghosh BK, Cerda JJ, Crane RK (1973) Purification of the human intestinal brush border membrane. Biochim Biophys Acta-Biomembr 323:98–112CrossRefGoogle Scholar
  16. Treiber A, Morand O, Clozel M (2007) The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 37:298–314PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  1. 1.Department of Physiological ChemistryUniversity of Veterinary Medicine HannoverHannoverGermany

Personalised recommendations